GoodRx Holdings, Inc. (GDRX) Stock Analysis and Metrics

GoodRx Holdings

NASDAQ: GDRX

$2.95 ▲ +0.08 (+2.79%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap977.32 Mn

P/E47.54

P/S1.24

Div. Yield0.00

ROIC (Qtr)0.02

Total Debt (Qtr)487.42 Mn

Revenue Growth (1y) (Qtr)-4.42

Add ratio to table…

About

GoodRx Holdings, Inc. operates a consumer focused digital healthcare platform in the United States that provides price transparency and affordability solutions for prescription medications and related healthcare services. The company’s mission is to help Americans save time and money when filling their medications by removing friction and inefficiencies in the system. Users can search for lower drug prices, access telehealth visits and subscribe to enhanced savings programs through the platform.

Revenue is generated primarily through fees paid by pharmacy benefit managers and pharmacies each time a consumer uses a GoodRx code to obtain a discounted prescription, through subscription fees for offerings such as Gold, RxSmartSaver+, and condition specific programs, and through payments from pharmaceutical manufacturers for advertising and integrating their affordability solutions on the platform. Additionally, the company earns revenue from telehealth visits offered via its subscription services, where patients pay for virtual consultations outside of insurance. These streams together constitute the core of GoodRx’s business model.

The company operates through the following segments: Prescription Marketplace, Subscription Offerings, and Pharma Direct Offering.

• Prescription Marketplace: This segment aggregates pricing data from pharmacy benefit managers, pharmacies, manufacturers, and other sources to deliver geographically relevant prescription prices and free GoodRx codes, earning revenue from fees paid by PBMs and pharmacies upon each code use while also providing consumers with tools to compare prices across nearby pharmacies and track savings over time.

• Subscription Offerings: This segment includes Gold, RxSmartSaver+, and condition specific programs that charge monthly or annual fees for enhanced discounts, mail delivery, telehealth access, and bundled care services, providing recurring revenue from subscribers and offering benefits such as lower drug prices at select pharmacies, free home delivery on eligible medications, and virtual consultations with healthcare professionals.

• Pharma Direct Offering: This segment partners with pharmaceutical manufacturers to advertise and integrate copay cards, patient assistance programs, and consumer direct pricing, earning fees for driving uptake of brand medication affordability solutions and helping manufacturers increase patient awareness, adherence, and overall demand for their products.

GoodRx holds a leading position in the U. S. prescription price transparency market, competing with fragmented coupon sites, large e commerce platforms, and health focused apps. Its competitive advantages stem from a proprietary pricing database that processes hundreds of billions of data points daily, extensive relationships with dozens of PBMs and pharmacy chains, and a strong consumer brand that drives high engagement and network effects. The company also benefits from high repeat usage of its discounts, which creates a durable moat as consumers return to the same pharmacy after realizing savings, reinforcing the value proposition for both users and partners. While new entrants may appear, the scale of data and network relationships required to replicate the platform presents a significant barrier to entry. The firm continues to invest in new product categories such as employer direct solutions and clinical trial enrollment tools to expand its addressable market.

The platform serves individual consumers seeking lower prescription costs, healthcare providers who use the tool to inform patients at the point of care, pharmacies that benefit from increased foot traffic and adherence programs, and pharmaceutical manufacturers that leverage the service to promote affordability initiatives. Consumers range from the uninsured looking for cash prices to insured individuals seeking lower out of pocket costs than their plan copays. Healthcare providers include physicians and pharmacists who integrate GoodRx pricing into electronic health records or recommend the service to patients during visits. While specific partner names are not disclosed in the excerpt, the company notes relationships with major pharmacy chains and numerous PBMs across the United States.

Investment Thesis

▲ Bull case

GoodRx's transition from a pure pricing solution to an access infrastructure platform is creating sustainable long-term growth beyond temporary market cycles, as evidenced by the company's strategic pivot toward higher-margin, recurring revenue streams like Pharma Direct and condition-specific subscriptions. The Q1 results show Pharma Direct revenue growing 82% year-over-year to $52.2 million, driven by manufacturer-sponsored pricing programs and GLP-1 access expansion, with the company now guiding for over 50% full-year growth in this segment. This growth is not merely cyclical but structural, as GoodRx has evolved into a channel where manufacturers leverage its platform to deliver self-pay programs directly to consumers at scale, positioning the company at the center of how medications are evaluated, accessed, and filled. The recent launch of GoodRx Companion—a $14.99-per-month subscription offering broader savings on generics, online care visits, and healthcare services—further diversifies the subscription model beyond condition-specific programs, tapping into the growing trend of consumers managing out-of-pocket costs even with insurance. This initiative strengthens GoodRx's ability to build deeper, more recurring consumer relationships across a growing portfolio, directly addressing the evolving healthcare landscape where affordability is becoming a central factor earlier in the patient journey. Management's emphasis on organic growth in subscriptions without heavy marketing spend—coupled with plans to increase investment in condition-specific offerings later in the year—suggests untapped upside potential as brand recognition and prescriber NPS continue to drive engagement.
The company's direct contracting model and broad retail network connectivity create a durable competitive advantage that is underappreciated by the market, particularly as pharmaceutical manufacturers accelerate direct-to-consumer strategies and employers seek new ways to support high-cost therapies. GoodRx's Pharma Direct business now enables manufacturers to reach patients directly through branded storefronts on the platform, with programs available across its nationwide pharmacy network, supporting broad consumer choice and convenient access—exemplified by the collaboration with Viatris for 17 established brand medications and significant Pfizer discounts on over 30 essential medications. This model represents a more cohesive and consumer-friendly way to present affordability offerings at scale, extending beyond pricing into a true access infrastructure. Furthermore, the extension of Pharma Direct into the employer channel via GoodRx Employer Direct allows self-insured employers to offer manufacturer-sponsored pricing with seamless employer subsidies, as demonstrated by the Eli Lilly partnership on Zepbound KwikPens, where employers can subsidize Lilly's $449 price across all doses without changing core benefit structures. This employer channel expansion creates a new, scalable revenue stream that leverages existing platform capabilities while addressing coverage gaps without requiring benefit redesign, positioning GoodRx to capture value from both consumer and enterprise sides of the healthcare ecosystem.
The stabilization of Monthly Active Consumers (MAC) at approximately 5.3 million, coupled with flat quarter-over-quarter trends and sequential stability despite macroeconomic headwinds, indicates that the core Rx Marketplace business is finding a durable floor rather than facing continued erosion, which management has consistently underplayed in its guidance. While prescription transaction revenue declined 24% year-over-year due to lapping impacts and unit economics pressure, the company noted that MAC was slightly up quarter-over-quarter (rounding to flat) and modeled continued erosion but at a much more flatlined trajectory than the prior year's decline. This stabilization is significant given the context of widening coverage gaps, elevated out-of-pocket costs, and increasing numbers of uninsured and underinsured Americans—factors that should theoretically drive higher engagement with affordability platforms like GoodRx. The fact that MAC is holding steady amid these trends suggests that the platform's value proposition is resonating, with consumers actively evaluating cost before prescribing and filling, and that any near-term pressure on PTR is likely temporary and tied to specific 2025 comps rather than a structural decline. Moreover, the interplay between PTR and Pharma Direct—where high-cost branded prescriptions shift from PTR to Pharma Direct via point-of-sale buydown programs—is not a cannibalization risk but a preferred strategic outcome, creating longer-term, durable revenue streams as consumers access the same medications through manufacturer-sponsored pricing rather than paying full price. This dynamic, which management acknowledged as "preferred to us," implies that the decline in PTR may be overstated as a concern, as it reflects successful execution of the company's strategic shift rather than fundamental weakness in consumer engagement.

GoodRx's transition from a pure pricing solution to an access infrastructure platform is creating sustainable long-term growth beyond temporary market cycles, as evidenced by the company's strategic pivot toward higher-margin, recurring revenue streams like Pharma Direct and condition-specific subscriptions. The Q1 results show Pharma Direct revenue growing 82% year-over-year to $52.2 million, driven by manufacturer-sponsored pricing programs and GLP-1 access expansion, with the company now guiding for over 50% full-year growth in this segment. This growth is not merely cyclical but structural, as GoodRx has evolved into a channel where manufacturers leverage its platform to deliver self-pay programs directly to consumers at scale, positioning the company at the center of how medications are evaluated, accessed, and filled. The recent launch of GoodRx Companion—a $14.99-per-month subscription offering broader savings on generics, online care visits, and healthcare services—further diversifies the subscription model beyond condition-specific programs, tapping into the growing trend of consumers managing out-of-pocket costs even with insurance. This initiative strengthens GoodRx's ability to build deeper, more recurring consumer relationships across a growing portfolio, directly addressing the evolving healthcare landscape where affordability is becoming a central factor earlier in the patient journey. Management's emphasis on organic growth in subscriptions without heavy marketing spend—coupled with plans to increase investment in condition-specific offerings later in the year—suggests untapped upside potential as brand recognition and prescriber NPS continue to drive engagement.
The company's direct contracting model and broad retail network connectivity create a durable competitive advantage that is underappreciated by the market, particularly as pharmaceutical manufacturers accelerate direct-to-consumer strategies and employers seek new ways to support high-cost therapies. GoodRx's Pharma Direct business now enables manufacturers to reach patients directly through branded storefronts on the platform, with programs available across its nationwide pharmacy network, supporting broad consumer choice and convenient access—exemplified by the collaboration with Viatris for 17 established brand medications and significant Pfizer discounts on over 30 essential medications. This model represents a more cohesive and consumer-friendly way to present affordability offerings at scale, extending beyond pricing into a true access infrastructure. Furthermore, the extension of Pharma Direct into the employer channel via GoodRx Employer Direct allows self-insured employers to offer manufacturer-sponsored pricing with seamless employer subsidies, as demonstrated by the Eli Lilly partnership on Zepbound KwikPens, where employers can subsidize Lilly's $449 price across all doses without changing core benefit structures. This employer channel expansion creates a new, scalable revenue stream that leverages existing platform capabilities while addressing coverage gaps without requiring benefit redesign, positioning GoodRx to capture value from both consumer and enterprise sides of the healthcare ecosystem.
The stabilization of Monthly Active Consumers (MAC) at approximately 5.3 million, coupled with flat quarter-over-quarter trends and sequential stability despite macroeconomic headwinds, indicates that the core Rx Marketplace business is finding a durable floor rather than facing continued erosion, which management has consistently underplayed in its guidance. While prescription transaction revenue declined 24% year-over-year due to lapping impacts and unit economics pressure, the company noted that MAC was slightly up quarter-over-quarter (rounding to flat) and modeled continued erosion but at a much more flatlined trajectory than the prior year's decline. This stabilization is significant given the context of widening coverage gaps, elevated out-of-pocket costs, and increasing numbers of uninsured and underinsured Americans—factors that should theoretically drive higher engagement with affordability platforms like GoodRx. The fact that MAC is holding steady amid these trends suggests that the platform's value proposition is resonating, with consumers actively evaluating cost before prescribing and filling, and that any near-term pressure on PTR is likely temporary and tied to specific 2025 comps rather than a structural decline. Moreover, the interplay between PTR and Pharma Direct—where high-cost branded prescriptions shift from PTR to Pharma Direct via point-of-sale buydown programs—is not a cannibalization risk but a preferred strategic outcome, creating longer-term, durable revenue streams as consumers access the same medications through manufacturer-sponsored pricing rather than paying full price. This dynamic, which management acknowledged as "preferred to us," implies that the decline in PTR may be overstated as a concern, as it reflects successful execution of the company's strategic shift rather than fundamental weakness in consumer engagement.

▼ Bear case

GoodRx's reliance on manufacturer-sponsored pricing programs in Pharma Direct introduces significant concentration risk and sustainability concerns that the market is overlooking, particularly as the company's growth in this segment is heavily dependent on a narrow set of high-profile therapies like GLP-1s and subject to volatile manufacturer priorities. While Pharma Direct revenue grew 82% year-over-year in Q1, this growth is disproportionately driven by a limited number of recent launches—including Ozempic Pill, Wegovy HD, Wegovy Pill, Boundeo, and Zepbound KwikPen—with the company itself acknowledging that it accounted for approximately one-third of all Wegovy Pill transactions in the first two months post-launch. This concentration makes the segment vulnerable to shifts in manufacturer strategy, pricing decisions, or competitive responses; for example, if Novo Nordisk or Eli Lilly decide to reduce their investment in GoodRx-mediated channels or shift focus to proprietary direct-to-consumer platforms, Pharma Direct growth could decelerate rapidly. Furthermore, the company's guidance for over 50% full-year Pharma Direct growth assumes continued momentum in these specific programs, yet there is no evidence of broad-based expansion across therapeutic areas beyond the highlighted collaborations (e.g., Viatris for 17 established brands, Pfizer on essential medications), which remain early-stage and unproven at scale. The lack of diversification in Pharma Direct's revenue base—coupled with the fact that these programs are often tied to specific manufacturer marketing budgets that can be pulled back—creates a fragile growth engine that may not be as durable as management suggests, especially in an environment where pharmaceutical companies are increasingly building their own direct-to-consumer capabilities.
The Rx Marketplace business faces structural headwinds that are being masked by temporary stabilization in Monthly Active Consumers (MAC), with long-term volume trends likely to deteriorate due to ongoing retail pharmacy consolidation, shifting consumer behavior, and the inherent limitations of the cash-pay pricing model in an evolving insurance landscape. Although management noted MAC was flat quarter-over-quarter and slightly up (rounding to flat), they acknowledged continued erosion in MAC modeled at a conservative level, reflecting deeper issues such as the lasting impact of Rite Aid store closures and the broader trend of retail concentration favoring larger chains like CVS and Walgreens. As stronger retail players take share from weaker ones, GoodRx's ability to monetize traffic may diminish if these chains negotiate less favorable terms or prioritize their own proprietary savings programs, reducing reliance on third-party platforms. Moreover, the core value proposition of GoodRx—providing transparent cash prices for prescriptions—is increasingly challenged by the rise of high-deductible health plans and accumulator adjustment programs, which can prevent cash payments from counting toward deductibles, thereby diminishing the financial incentive for consumers to use the service even when out-of-pocket costs are high. This dynamic is exacerbated by the fact that GoodRx does not deal with compounded drugs or gross up branded drug revenue in its P&L, limiting its ability to capture value from alternative pricing models that competitors may be leveraging. Without a meaningful shift in how the platform integrates with insurance adjudication or value-based care frameworks, the Rx Marketplace remains vulnerable to secular decline, and the current stabilization in MAC may merely represent a temporary pause before renewed downward pressure.
GoodRx's subscription strategy, while showing early signs of growth, is vulnerable to intense competition and questionable unit economics, particularly as the company attempts to expand beyond condition-specific offerings into broader membership models like GoodRx Companion, which may struggle to justify its $14.99 price point in a crowded market of healthcare subscriptions. Although subscription revenue grew 16% year-over-year to $24.4 million in Q1, this growth is largely driven by the weight loss offering (GoodRx for weight loss), with management acknowledging that ED and hair loss offerings contribute only marginally to growth. The launch of Companion—a $14.99-per-month bundle combining generics, online care visits, and healthcare service savings—represents a strategic shift toward a more diversified membership model, yet it enters a market saturated with similar offerings from employers, insurers, and digital health platforms that often bundle these services at lower costs or as part of existing benefits. The company's claim that Companion provides "greater control and clearer value" is undermined by the lack of disclosed metrics on consumer adoption, retention, or average revenue per user beyond the initial price point, and the fact that marketing spend for subscriptions was actually down year-over-year in Q1 despite the stated focus on condition-specific programs. This suggests that early traction may be driven by existing brand recognition rather than genuine product-market fit, and as competition intensifies from telehealth platforms, pharmacies, and manufacturers building their own direct-to-consumer capabilities (as noted in the Maxi Ma question), GoodRx's ability to sustain subscription growth without significantly increased customer acquisition costs is doubtful. Moreover, the reliance on a $39 monthly fee for GLP-1 subscriptions—where only the fee is recognized in subscription revenue while the drug cost flows through Pharma Direct—creates a fragmented monetization model that may confuse consumers and limit pricing power, especially as competitors offer more integrated experiences that include the actual medication cost in their pricing.

GoodRx's reliance on manufacturer-sponsored pricing programs in Pharma Direct introduces significant concentration risk and sustainability concerns that the market is overlooking, particularly as the company's growth in this segment is heavily dependent on a narrow set of high-profile therapies like GLP-1s and subject to volatile manufacturer priorities. While Pharma Direct revenue grew 82% year-over-year in Q1, this growth is disproportionately driven by a limited number of recent launches—including Ozempic Pill, Wegovy HD, Wegovy Pill, Boundeo, and Zepbound KwikPen—with the company itself acknowledging that it accounted for approximately one-third of all Wegovy Pill transactions in the first two months post-launch. This concentration makes the segment vulnerable to shifts in manufacturer strategy, pricing decisions, or competitive responses; for example, if Novo Nordisk or Eli Lilly decide to reduce their investment in GoodRx-mediated channels or shift focus to proprietary direct-to-consumer platforms, Pharma Direct growth could decelerate rapidly. Furthermore, the company's guidance for over 50% full-year Pharma Direct growth assumes continued momentum in these specific programs, yet there is no evidence of broad-based expansion across therapeutic areas beyond the highlighted collaborations (e.g., Viatris for 17 established brands, Pfizer on essential medications), which remain early-stage and unproven at scale. The lack of diversification in Pharma Direct's revenue base—coupled with the fact that these programs are often tied to specific manufacturer marketing budgets that can be pulled back—creates a fragile growth engine that may not be as durable as management suggests, especially in an environment where pharmaceutical companies are increasingly building their own direct-to-consumer capabilities.
The Rx Marketplace business faces structural headwinds that are being masked by temporary stabilization in Monthly Active Consumers (MAC), with long-term volume trends likely to deteriorate due to ongoing retail pharmacy consolidation, shifting consumer behavior, and the inherent limitations of the cash-pay pricing model in an evolving insurance landscape. Although management noted MAC was flat quarter-over-quarter and slightly up (rounding to flat), they acknowledged continued erosion in MAC modeled at a conservative level, reflecting deeper issues such as the lasting impact of Rite Aid store closures and the broader trend of retail concentration favoring larger chains like CVS and Walgreens. As stronger retail players take share from weaker ones, GoodRx's ability to monetize traffic may diminish if these chains negotiate less favorable terms or prioritize their own proprietary savings programs, reducing reliance on third-party platforms. Moreover, the core value proposition of GoodRx—providing transparent cash prices for prescriptions—is increasingly challenged by the rise of high-deductible health plans and accumulator adjustment programs, which can prevent cash payments from counting toward deductibles, thereby diminishing the financial incentive for consumers to use the service even when out-of-pocket costs are high. This dynamic is exacerbated by the fact that GoodRx does not deal with compounded drugs or gross up branded drug revenue in its P&L, limiting its ability to capture value from alternative pricing models that competitors may be leveraging. Without a meaningful shift in how the platform integrates with insurance adjudication or value-based care frameworks, the Rx Marketplace remains vulnerable to secular decline, and the current stabilization in MAC may merely represent a temporary pause before renewed downward pressure.
GoodRx's subscription strategy, while showing early signs of growth, is vulnerable to intense competition and questionable unit economics, particularly as the company attempts to expand beyond condition-specific offerings into broader membership models like GoodRx Companion, which may struggle to justify its $14.99 price point in a crowded market of healthcare subscriptions. Although subscription revenue grew 16% year-over-year to $24.4 million in Q1, this growth is largely driven by the weight loss offering (GoodRx for weight loss), with management acknowledging that ED and hair loss offerings contribute only marginally to growth. The launch of Companion—a $14.99-per-month bundle combining generics, online care visits, and healthcare service savings—represents a strategic shift toward a more diversified membership model, yet it enters a market saturated with similar offerings from employers, insurers, and digital health platforms that often bundle these services at lower costs or as part of existing benefits. The company's claim that Companion provides "greater control and clearer value" is undermined by the lack of disclosed metrics on consumer adoption, retention, or average revenue per user beyond the initial price point, and the fact that marketing spend for subscriptions was actually down year-over-year in Q1 despite the stated focus on condition-specific programs. This suggests that early traction may be driven by existing brand recognition rather than genuine product-market fit, and as competition intensifies from telehealth platforms, pharmacies, and manufacturers building their own direct-to-consumer capabilities (as noted in the Maxi Ma question), GoodRx's ability to sustain subscription growth without significantly increased customer acquisition costs is doubtful. Moreover, the reliance on a $39 monthly fee for GLP-1 subscriptions—where only the fee is recognized in subscription revenue while the drug cost flows through Pharma Direct—creates a fragmented monetization model that may confuse consumers and limit pricing power, especially as competitors offer more integrated experiences that include the actual medication cost in their pricing.

Peer Comparison

Companies in the Health Information Services

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	VEEV	Veeva Systems Inc	29.34 Bn	31.16	8.84	-
2	BTSG	BrightSpring Health Services, Inc.	13.49 Bn	46.18	0.99	2.50 Bn
3	HQY	Healthequity, Inc.	7.96 Bn	34.51	5.95	0.94 Bn
4	TXG	10x Genomics, Inc.	6.17 Bn	-272.14	9.65	-
5	HNGE	Hinge Health, Inc.	6.02 Bn	-11.77	9.31	-
6	MMED	MiniMed Group, Inc.	4.19 Bn	-8.88	1.38	-
7	WAY	Waystar Holding Corp.	4.14 Bn	32.80	3.58	1.47 Bn
8	DOCS	Doximity, Inc.	3.82 Bn	19.51	5.93	-

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password